Consensus Praxis Precision Medicines, Inc.

Equities

PRAX

US74006W2070

Market Closed - Nasdaq Other stock markets 21:00:00 01/05/2024 BST			5-day change	1st Jan Change
55.16 ^USD	+0.53%		+12.94%	+147.58%

05-01	Baird Initiates Praxis Precision Medicines With Outperform Rating, $117 Price Target	MT
04-11	Certain Common Stock of Praxis Precision Medicines, Inc. are subject to a Lock-Up Agreement Ending on 11-APR-2024.	CI

Evolution of the average Target Price on Praxis Precision Medicines, Inc.

Price target over the last 5 years

History of analyst recommendation changes

7032463.hu7vtS7RmdF2oBQTqL3dKXrTPik2koVh2DEi-pPZznk.7LiJ-GGbr5QQlCUg2vSCZTS2dkh1y-EZkHlVkKTqjRb8sd_WW7XO_ByUWQ~1483edd54f7c07fce6e69f6fe0fc4f33

Analyst Recommendations on Praxis Precision Medicines, Inc.

Baird Initiates Praxis Precision Medicines With Outperform Rating, $117 Price Target	05-01	MT
Wedbush Trims Price Target on Praxis Precision Medicines to $40 From $41 After $200 Million Secondary Offering, Maintains Neutral Rating	04-08	MT
Jefferies Adjusts Praxis Precision Medicines' Price Target to $128 From $75, Keeps Buy Rating	03-26	MT
Wedbush Adjusts Praxis Precision Medicines' Price Target to $41 From $29, Maintains Neutral Rating	03-05	MT
North American Morning Briefing : Rate Doubts Keep -2-	02-06	DJ
Wedbush Adjusts Praxis Precision Medicines' Price Target to $16 From $15 After Reverse Stock Split, Keeps Neutral Rating	11-30	MT
Wedbush Trims Praxis Precision Medicines' PT to $1 From $2 After 'Relatively Uneventful' Q3 Results; Keeps Neutral Rating	11-07	MT
Truist Initiates Praxis Precision Medicines at Buy With $10 Price Target	19/09/23	MT
HC Wainwright Adjusts Price Target on Praxis Precision Medicines to $7 From $15, Keeps Buy Rating	10/08/23	MT
Jefferies Starts Praxis Precision Medicines at Buy With $4 Price Target	02/06/23	MT
William Blair Downgrades Praxis Precision Medicines to Market Perform Rating From Outperform	06/03/23	MT
Wedbush Adjusts Praxis Precision Medicines Price Target to $2 From $3, Maintains Neutral Rating	03/03/23	MT
HC Wainwright Reiterates Praxis Precision Medicines at Buy With $16 Price Target	03/02/23	MT
Wedbush Trims Praxis Precision Medicines' Price Target to $3 From $4 After Increased Financing Assumptions, Keeps Neutral Rating	10/11/22	MT
Piper Sandler Adjusts Price Target on Praxis Precision Medicines to $18 From $65, Reiterates Overweight Rating	08/06/22	MT
HC Wainwright Adjusts Price Target on Praxis Precision Medicines to $10 From $48, Reiterates Buy Rating	07/06/22	MT
BofA Securities Cuts Praxis Precision Medicines to Neutral From Buy, Price Target to $4 From $26	07/06/22	MT
Wedbush Downgrades Praxis Precision Medicines to Neutral From Outperform, Adjusts Price Target to $4 From $34	06/06/22	MT
Wedbush Adjusts Price Target on Praxis Precision Medicines to $34 From $40, Keeps Outperform Rating	10/05/22	MT
Wedbush Trims Price Target on Praxis Precision Medicines to $40 From $42, Keeps Outperform Rating	28/04/22	MT
Wedbush Adjusts Price Target on Praxis Precision Medicines to $42 From $45, Citing PRAX-562 Launch Estimate; Outperform Rating Kept	28/02/22	MT
HC Wainwright Starts Praxis Precision Medicines at Buy With $48 Price Target	16/12/21	MT
Wedbush Adjusts Price Target on Praxis Precision Medicines to $45 From $50; Outperform Rating Kept	04/11/21	MT
PRAXIS PRECISION MEDICINES : BofA Securities Starts Praxis Precision Medicines at Buy With $28 Price Target	26/08/21	MT
PRAXIS PRECISION MEDICINES : Wedbush Adjusts Praxis Precision Medicines PT to $50 From $55, Maintains Outperform Rating	16/08/21	MT